News
As in the SMART trial, early hemodynamic differences have yet to result in a clinical impact—but it may just be a matter of ...
The FDA has approved the SAPIEN 3 platform, a TAVR therapy, for patients with severe aortic stenosis without symptoms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback